Tirzepatide 30 mg

TZ-2026-038Lot GLP2RPAnalyzed November 6, 2026

Timeline

Ordered

October 29, 2026

Received

November 4, 2026

Analyzed

November 6, 2026

Sample

Name

Tirzepatide 30 mg

Expected

Tirzepatide

Amount

1 vial, lyophilized powder

Testing

Client

Rivia Peptides

Test type

Content & purity

Method

HPLC-UV

Content, how much is in it

31.12mg

Label claim: 30 mg

Purity, how clean it is

99.6%

by HPLC-UV peak area, system peaks excluded

Chromatogram

HPLC-UV

18.99 min, Tirzepatide, 99.6%

Analyst Comments

White lyophilized powder, pink-cap vial, received sealed.

Analyst Signature

Max Barrett

Lab Director, PuriLab Analytical

Analysis date: November 6, 2026

Verification Code

TZ-JF5Q-VADH

Verify at purilab.org/verify/TZ-JF5Q-VADH

Scan to Verify

TZ-JF5Q-VADH

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.

PuriLab Analytical|admin@purilab.org

Page 1 of 1